| Issue Date |
Title |
Author(s) |
| 2016 |
Albumin Binding Function: The Potential Earliest Indicator for Liver Function Damage |
Ge, Penglei;Yang, Huayu;Lu, Jingfen;Liao, Wenjun;Du, Shunda;Xu, Yingli;Xu, Haifeng;Zhao, Haitao;Lu, Xin;Sang, Xinting;Zhong, Shouxian;Huang, Jiefu;Mao, Yilei |
| 2021 |
Cell-free DNA copy number variations predict efficacy of immune checkpoint inhibitor-based therapy in hepatobiliary cancers |
Yang, Xu;Hu, Ying;Yang, Keyan;Wang, Dongxu;Lin, Jianzhen;Long, Junyu;Xie, Fucun;Mao, Jinzhu;Bian, Jin;Guan, Mei;Pan, Jie;Huo, Li;Hu, Ke;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Zhang, Jiao;Wang, Xi;Zhang, Henghui;Zhao, Haitao |
| Nov-2021 |
Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition) |
Sun, Hui-Chuan;Zhou, Jian;Wang, Zheng;Liu, Xiufeng;Xie, Qing;Jia, Weidong;Zhao, Ming;Bi, Xinyu;Li, Gong;Bai, Xueli;Ji, Yuan;Xu, Li;Zhu, Xiao-Dong;Bai, Dousheng;Chen, Yajin;Chen, Yongjun;Dai, Chaoliu;Guo, Rongping;Guo, Wenzhi;Hao, Chunyi;Huang, Tao;Huang, Zhiyong;Li, Deyu;Li, Gang;Li, Tao;Li, Xiangcheng;Liang, Xiao;Liu, Jingfeng;Liu, Fubao;Lu, Shichun;Lu, Zheng;Lv, Weifu;Mao, Yilei;Shao, Guoliang;Shi, Yinghong;Song, Tianqiang;Tan, Guang;Tang, Yunqiang;Tao, Kaishan;Wan, Chidan;Wang, Guangyi;Wang, Lu;Wang, Shunxiang;Wen, Tianfu;Xing, Baocai;Xiang, Bangde;Yan, Sheng;Yang, Dinghua;Yin, Guowen;Yin, Tao;Yin, Zhenyu;Yu, Zhengping;Zhang, Bixiang;Zhang, Jialin;Zhang, Shuijun;Zhang, Ti;Zhang, Yamin;Zhang, Yubao;Zhang, Aibin;Zhao, Haitao;Zhou, Ledu;Zhang, Wu;Zhu, Zhenyu;Qin, Shukui;Shen, Feng;Cai, Xiujun;Teng, Gaojun;Cai, Jianqiang;Chen, Minshan;Li, Qiang;Liu, Lianxin;Wang, Weilin;Liang, Tingbo;Dong, Jiahong;Chen, Xiaoping;Wang, Xuehao;Zheng, Shusen;Fan, Jia |
| 9-Dec-2022 |
Efficacy of immune checkpoint inhibitors plus molecular targeted agents after the progression of lenvatinib for advanced hepatocellular carcinoma |
Xie, Fucun;Chen, Bowen;Yang, Xu;Wang, Huaiyuan;Zhang, Ge;Wang, Yanyu;Wang, Yunchao;Zhang, Nan;Xue, Jingnan;Long, Junyu;Li, Yiran;Sun, Huishan;Xun, Ziyu;Liu, Kai;Chen, Xiangqi;Song, Yang;Yang, Xiaobo;Lu, Zhenhui;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Haitao |
| 6-Aug-2021 |
Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancer |
Lin, Jianzhen;Peng, Xinxin;Dong, Kun;Long, Junyu;Guo, Xuejiao;Li, Hongyue;Bai, Yi;Yang, Xu;Wang, Dongxu;Lu, Xin;Mao, Yilei;Sang, Xinting;Ji, Xuwo;Zhao, Haitao;Liang, Han |
| 2019 |
Landscape and Dynamics of Single Immune Cells in Hepatocellular Carcinoma |
Zhang, Qiming;He, Yao;Luo, Nan;Patel, Shashank J.;Han, Yanjie;Gao, Ranran;Modak, Madhura;Carotta, Sebastian;Haslinger, Christian;Kind, David;Peet, Gregory W.;Zhong, Guojie;Lu, Shuangjia;Zhu, Weihua;Mao, Yilei;Xiao, Mengmeng;Bergmann, Michael;Hu, Xueda;Kerkar, Sid P.;Vogt, Anne B.;Pflanz, Stefan;Liu, Kang;Peng, Jirun;Ren, Xianwen;Zhang, Zemin |
| 1-Jun-2022 |
Lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma: A large real-world study from two centers. |
Yang, Xu;Chen, Bowen;Wang, Yanyu;Wang, Yunchao;Long, Junyu;Zhang, Nan;Xue, Jinnan;Xun, Ziyu;Zhang, Linzhi;Cheng, Jiamin;Lei, Jin;Pan, Jie;Hu, Ke;Guan, Mei;Huo, Li;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Hai-Tao |
| 2021 |
Mutational spectrum and precision oncology for biliary tract carcinoma |
Lin, Jianzhen;Cao, Yinghao;Yang, Xu;Li, Guangyu;Shi, Yang;Wang, Dongxu;Long, Junyu;Song, Yang;Mao, Jinzhu;Xie, Fucun;Bai, Yi;Zhang, Lei;Yang, Xiaobo;Wan, Xueshuai;Wang, Anqiang;Guan, Mei;Zhao, Lin;Hu, Ke;Pan, Jie;Huo, Li;Lu, Xin;Mao, Yilei;Sang, Xinting;Zhang, Henghui;Wang, Kai;Wang, Xiaoyue;Zhao, Haitao |
| Aug-2020 |
Pembrolizumab combined with lenvatinib as non-first-line therapy in patients with refractory biliary tract carcinoma |
Lin, Jianzhen;Yang, Xu;Long, Junyu;Zhao, Songhui;Mao, Jinzhu;Wang, Dongxu;Bai, Yi;Bian, Jin;Zhang, Lei;Yang, Xiaobo;Wang, Anqiang;Xie, Fucun;Shi, Weiwei;Yang, Huayu;Pan, Jie;Hu, Ke;Guan, Mei;Zhao, Lin;Huo, Li;Mao, Yilei;Sang, Xinting;Wang, Kai;Zhao, Haitao |
| Feb-2023 |
Real-world efficacy and prognostic factors of lenvatinib plus PD-1 inhibitors in 378 unresectable hepatocellular carcinoma patients |
Yang, Xu;Chen, Bowen;Wang, Yanyu;Wang, Yunchao;Long, Junyu;Zhang, Nan;Xue, Jingnan;Xun, Ziyu;Zhang, Linzhi;Cheng, Jiamin;Lei, Jin;Sun, Huishan;Li, Yiran;Lin, Jianzhen;Xie, Fucun;Wang, Dongxu;Pan, Jie;Hu, Ke;Guan, Mei;Huo, Li;Shi, Jie;Yu, Lingxiang;Zhou, Lin;Zhou, Jinxue;Lu, Zhenhui;Yang, Xiaobo;Mao, Yilei;Sang, Xinting;Lu, Yinying;Zhao, Haitao |
| 2016 |
Reduction in albumin binding function following liver resection in patients with and without cirrhosis |
Ge, Penglei;Liao, Wenjun;Yang, Huayu;Lu, Jingfen;Xu, Wei;Hu, Dandan;Du, Shunda;Xu, Haifeng;Zhao, Haitao;Lu, Xin;Sang, Xinting;Zhong, Shouxian;Huang, Jiefu;Mao, Yilei |
| 2017 |
Wip1-/- ameliorates hepatic ischemia/reperfusion injury via PI3K/Akt activation |
Yang, Huayu;Li, Chang;Huang, Wei;Guo, Wei;Cui, Jingrong;Sang, Xinting;Mao, Yilei |
